Evidence map›Paper›PMID 35372430›Full record

ArticleFrontiers in medicine2022

Psychotropic Medication Use Is Associated With Greater 1-Year Incidence of Dementia After COVID-19 Hospitalization.

Yun Freudenberg-Hua, Alexander Makhnevich, Wentian Li, Yan Liu, Michael Qiu, Allison Marziliano, Maria Carney, Blaine Greenwald, John M Kane, Michael Diefenbach and 3 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. The Role of Psychobiotics to Ensure Mental Health during the COVID-19 Pandemic-A Current State of Knowledge.International journal of environmental research and public health · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yun Freudenberg-HuaDepartment of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, United States.
Alexander MakhnevichThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Wentian LiThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Yan LiuThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Michael QiuThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Allison MarzilianoThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Maria CarneyThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Blaine GreenwaldDepartment of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, United States.
John M KaneDepartment of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, United States.
Michael DiefenbachThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Edith BurnsThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Jeremy KoppelDepartment of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, United States.
Liron SinvaniThe Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.

Funding

Identification of Risk Genes SupplementK08AG054727 · NIA · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI FREUDENBERG-HUA, YUN · 2017 to 2022
$739k
NIA NIH HHS K08 AG054727
6 · The paper itself

Abstract

Background: COVID-19 has been associated with an increased risk of incident dementia (post-COVID dementia). Establishing additional risk markers may help identify at-risk individuals and guide clinical decision-making. Methods: We investigated pre-COVID psychotropic medication use (exposure) and 1-year incidence of dementia (outcome) in 1,755 patients (≥65 years) hospitalized with COVID-19. Logistic regression models were used to examine the association, adjusting for demographic and clinical variables. For further confirmation, we applied the Least Absolute Shrinkage and Selection Operator (LASSO) regression and a machine learning (Random Forest) algorithm. Results: One-year incidence rate of post-COVID dementia was 12.7% ( Conclusion: Confirming prior studies we observed a high dementia incidence in older patients after COVID-19 hospitalization. Pre-COVID psychotropic medications were associated with higher risk of incident dementia. Psychotropic medications may be risk markers that signify neuropsychiatric symptoms during prodromal dementia, and not mutually exclusive, contribute to post-COVID dementia.

Indexed as

cognitive impairmentCOVID-19dementiageriatricpost-COVIDpsychotropic medication

Identifiers

PMID35372430
PMCPMC8972194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.